Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)

Approval based on results from Phase 3 trial showing Dupixent significantly reduced itch compared to placebo CSU is the fifth approved indication for Dupixent in Japan and the sixth indication for...

Related Keywords

Japan ,Paris ,France General ,France ,Japanese ,Sally Bain ,Evan Berland ,Arnaud Delepine ,Nathalie Pham ,Georged Yancopoulos ,Corentine Driancourt ,Regeneron Velocimmune ,Tarik Elgoutni ,Felix Lauscher ,Vesna Tosic ,Ilana Yellen ,Eva Schaefer Jansen ,Linkedin ,Regeneron Genetics Center ,Dupilumab Development Program ,Exchange Commission ,Ministry Of Health ,Euronext ,Regeneron Pharmaceuticals Inc ,Regeneron Velocimmune Technology ,Nasdaq ,Chief Scientific Officer George ,Nasal Polyposis ,Prescribing Information ,Forward Looking Statements ,Regeneron Pharmaceuticals ,Product Candidates ,Private Securities Litigation Reform Act ,Statement Regarding Forward Looking ,Markets ,